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Introduction {#sec1}
============

Risk variants for neurodevelopmental disorders such as schizophrenia (SZ) include both common single-nucleotide variants (SNVs) with small effects sizes ([@bib41]) and copy-number variations (CNVs) with greater penetrance ([@bib9]). The majority of SZ-associated SNVs reside in genomic loci outside of coding regions ([@bib41]), and may function as *cis*-acting expression quantitative trait loci (*cis*-eQTLs) ([@bib13]); however, they are frequently associated with genes that have limited functional annotation, making the connection between gene function and disease risk difficult to untangle. Moreover, because SZ-associated CNVs are large structural deletions or duplications of genomic sequence that generally encompass multiple genes ([@bib9]), defining the gene(s) responsible for disease risk can be difficult to resolve.

Designing reverse genetic experiments to ascertain the function of SZ-associated genes is hampered by the paucity of (and inability to manipulate) postmortem tissue from SZ patients. Human-induced pluripotent stem cell (hiPSC)-derived neural cells represent a novel strategy by which to model the genes underlying SZ predisposition. Using hiPSC-derived neural cells, we have previously demonstrated aberrant gene expression, protein levels and migration in SZ hiPSC-derived neural progenitor cells (NPCs) ([@bib2], [@bib47], [@bib48]), and diminished neuronal connectivity and synaptic activity in SZ hiPSC-derived neurons ([@bib1], [@bib56]). Although these hiPSC-based studies partially reflect postmortem pathological ([@bib51]) and SZ-rodent model (well-reviewed by [@bib21]) findings, the precise functional dissection of SZ "risk genes" in hiPSC neuronal models has been challenging, except for small studies of rare families with SZ-associated inherited mutations ([@bib27], [@bib44], [@bib50], [@bib55], [@bib59]). The ability to precisely modulate SZ disease-relevant gene expression in hiPSC-derived neural cell types would allow hiPSC models to better define the contribution and function of more genes associated with SZ disease risk.

The bacterial type II clustered regularly interspaced short palindromic repeat (CRISPR) and CRISPR-associated (Cas) protein system of *Streptococcus pyogenes* evolved as a component of the prokaryotic immune system ([@bib23]) and has recently been repurposed for editing of the human genome ([@bib8]). When complexed with an artificial single guide RNA (gRNA) to form an RNA-guided endonuclease, Cas9 can be directed to almost any genomic location, provided that the 20 base pair nucleotide gRNA target sequence satisfies the protospacer-adjacent motif requirement ([@bib8]). Such limited target sequence requirements, together with the simplicity and ease of cloning synthesized gRNAs, has led to novel applications beyond genome editing. By simultaneously introducing nuclease-null mutations into Cas9 ([@bib14], [@bib37]), and coupling the catalytically inactive or dead Cas9 (dCas9) to a variety of effector protein domains, the modulation of transcription ([@bib14], [@bib37]), DNA methylation ([@bib33], [@bib49]), and histone modifications ([@bib16]) have all been demonstrated. Activation or repression of transcription using dCas9-fusion protein variants represents a novel methodology to design gain- or loss-of-function studies with high fidelity. As this modulation occurs at the endogenous level, it is predicted to include the full range of alternative splice isoforms, which are frequently overlooked by RNAi technologies or the use of cDNA overexpression approaches. While a growing number of proof-of-concept studies have demonstrated the successful application of a variety of dCas9-fusion proteins to the up- and downregulation of endogenous expression, few, if any, have systematically described the inter-gene, inter-individual, inter-cell type, and inter-effector variation in the practical application of this system.

Using hiPSC-derived neural cells, we set out to systemically test the ability of different gRNAs targeting the presumptive promoter regions of five different SZ-associated risk genes: potassium channel tetramerization domain containing 13 (*KCTD13*) and thousand and one amino acid protein kinase 2 (*TOAK2*) resides within 16p11.2, and neurexin 1 (*NRXN1*) within 2p16.3, two loci where recurrent CNVs are associated with intellectual disability, autism spectrum disorder, SZ, and other neuropsychiatric disorders ([@bib9], [@bib32]), whereas synaptosome-associated protein 91 (*SNAP91*) and chloride voltage-gated channel 3 (*CLCN3*) have both recently been implicated with SZ risk via *cis*-eQTLs genome-wide association study variant analysis ([@bib13]). By evaluating dCas9-mediated transcriptional modulation using three different platforms (downregulation using a dCas9 fusion to the Krüppel-associated box \[KRAB\] repressor domain \[[@bib46]\]; upregulation using a dCas9 fusion to the tetrameric VP16 transcription activator domain \[VP64\] \[[@bib24], [@bib31]\] or the tripartite activator, VP64-p65-Rta (VPR) \[[@bib6], [@bib7]\]), in three different hiPSC-derived neural cell types (NPCs, neurons, and astrocytes) ([Figure 1](#fig1){ref-type="fig"}), using hiPSCs reprogrammed from three unique donors ([Table S1](#mmc1){ref-type="supplementary-material"}), we describe the efficacy and variability of dCas9-protein fusion-based transcriptional modulation in hiPSC-based studies.Figure 1Experimental Platform to Evaluate dCas9-Mediated Manipulation of Gene Expression in hiPSC-Derived NPCs, Neurons, and Astrocytes(A) Experimental schematic for the generation of hiPSC-derived NPCs, neurons, and astrocytes, including the administration of lentiviral dCas9 and gRNA vectors.(B) Experimental time line for lentiviral transduction (and antibiotic selection) of hiPSC-derived NPCs, neurons, and astrocytes with lentiviral dCas9 and gRNA vectors.(C) gRNA locations (green, blue, and yellow) relative to the TSS of *KCTD13, TAOK2, NRXN1, SNAP91*, and *CLCN3*.

Results {#sec2}
=======

Gene expression profiling indicates that our hiPSC NPCs most resemble cells in the fetal cortical and subcortical forebrain regions ([@bib2]). NPCs are a replicative population of SOX2-positive and NESTIN-positive cells with the capacity to differentiate to populations comprised of ∼80% neurons (predominantly excitatory) and ∼20% astrocytes ([@bib1]). Lentiviral transduction of NPCs with doxycycline-inducible human *NGN2* rapidly yields excitatory neurons with robust electrical activity and detectable synaptic puncta within 3 weeks ([@bib17]); they can also be differentiated to a population of hiPSC-astrocytes that shares the transcriptional profile and functional characteristics of human fetal astrocytes via a 30-day protocol ([@bib45]). qPCR characterization of hiPSC-derived NPCs, neurons, *NGN2* neurons, and astrocytes demonstrated baseline expression of all five SZ-risk genes considered herein, *KCTD13, TOAK2, NRXN1, SNAP91,* and *CLCN3* ([Figure S1](#mmc1){ref-type="supplementary-material"}), prior to dCas9-manipulation.

The Efficacy of dCas9-Mediated Transcript Activation Varies Extensively between Genes and Is Not Necessarily Consistent between Unique Donors {#sec2.1}
---------------------------------------------------------------------------------------------------------------------------------------------

A variety of human genes (*VEGFA, NTF3* \[[@bib31]\], *SOX2* \[[@bib24]\], and *ASCL1, NEUROD1, MIAT1,* and *RHOFX2* \[[@bib6], [@bib7]\]) have now been activated using dCas9 effectors in HEK293T cells or hiPSCs, although the extent to which any given gene is amenable to upregulation across a larger number of cell types is unclear; here we applied two well-established dCas9 transcriptional activators, dCas9^−VP64^ and dCas9^−VPR^, to hiPSC-derived NPCs and neurons ([Figures 1](#fig1){ref-type="fig"}A and 1B). As extensive transcriptional variability exists between hiPSCs from different donors ([@bib3], [@bib36], [@bib38]), we first considered how well the activating capabilities of both platforms translated across five genes ([Figure 1](#fig1){ref-type="fig"}C) using neural cells from three unique donors. For each gene, gRNAs were designed to target at least three distinct locations upstream of the transcriptional start site (TSS), and thus within the putative promoter elements ([Figure 1](#fig1){ref-type="fig"}C; [Table S2](#mmc1){ref-type="supplementary-material"}). Both antibiotic-selected ([Figure S2](#mmc1){ref-type="supplementary-material"}) and non-selected lentiviral-transduced dCas9^−VP64^ and dCas9^−VPR^ NPCs were evaluated.

First, transcriptional modulation of *KCTD13* and *TOAK2* was evaluated in NPCs. Across hiPSC-NPC lines from three unique donors, following the transduction of different lentiviruses encoding three distinct gRNAs, two *KCTD13* gRNAs (2 and 3) significantly increased *KCTD13* in dCas9^−VP64^ NPCs from two of the three individuals tested (gRNA 2: C1, 2.22-fold, p ≤ 0.01; C2, 1.87-fold, p ≤ 0.01; n = 3 each; gRNA 3: C1, 1.85-fold, p ≤ 0.05; C2, 1.48-fold, p ≤ 0.05; n = 3 each; antibiotic selection for dCas9^−VP64^) ([Figure 2](#fig2){ref-type="fig"}A). Activation of *TOAK2* by gRNAs targeted to three different locations upstream of the TSS failed to increase expression in dCas9^−VP64^ NPCs across both individuals tested (antibiotic selection for dCas9^−VP64^) ([Figure 2](#fig2){ref-type="fig"}B).Figure 2Activation of Neuropsychiatric Disorder Risk Genes in hiPSC-Derived NPCs and *NGN2* Neurons from Three Individuals(A--F) Normalized relative mRNA levels (compared with no gRNA or scrambled gRNA control as indicated \[gray\]) following transduction of dCas9^VP64^ (A, B, C, and E) and dCas9^VPR^ (C, D, and F) in NPCs (A, B, C, and E) and 8-day-old *NGN2* neurons (D and F) with lentivirus-expressing gRNAs targeted to three different locations (green, blue, and yellow) upstream of the TSS for *KCTD13* (A), *TAOK2* (B), *NRXN1* (C), *SNAP91* (D and E), and *CLCN3* (F). C1--C3 indicates hiPSC lines from three independent male controls (see [Table S1](#mmc1){ref-type="supplementary-material"} for more information); each biological replicate is depicted by a circle.Data are presented as means ± SEM (bar graph) from at least three independent biological replicates. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001.

Second, across six gRNAs generated to the promoter regions to *NRXN1*, we failed to observe robust increases in expression with either dCas9^−VP64^ or dCas9^−VPR^ NPCs ([Figures 2](#fig2){ref-type="fig"}C and [S3](#mmc1){ref-type="supplementary-material"}), only achieving increased *NRXN1* expression in one individual with one gRNA using either the dCas9^−VP64^ and dCas9^−VPR^ effectors (gRNA 2: dCas9^−VP64^ C3, 5.66-fold, p ≤ 0.0001; dCas9^−VPR^ C3, 8.53-fold, p ≤ 0.05; n = 3 each; antibiotic selection for dCas9^−VP64^ and dCas9^−VPR^) ([Figure 2](#fig2){ref-type="fig"}C). Three additional gRNAs, designed upstream of a second TSS, were also unable to increase *NRXN1* expression, with or without selection for dCas9^−VP64^ in one individual ([Figure S3](#mmc1){ref-type="supplementary-material"}), demonstrating that testing up to six gRNAs does not ensure successful gene activation.

Third, highly expressed in neurons ([@bib58]), *SNAP91* and *CLCN3* transcriptional modulation was tested in *NEUROGENIN2* (*NGN2*)-induced populations of excitatory neurons ([@bib17], [@bib57]) after 8 days of maturation. Following transduction of three distinct gRNAs to *SNAP91,* in parallel with a lentivirus containing inducible *NGN2*, we found that gRNA 2 significantly increased *SNAP91* levels in dCas9^−VPR^ day 8 *NGN2* neurons from all three donors (gRNA 2: C1, 1.33-fold, p ≤ 0.01; C2, 1.66-fold, p ≤ 0.01; C3, 2.02-fold, p ≤ 0.001; n = 3 each; no antibiotic selection for dCas9^−VPR^) ([Figure 2](#fig2){ref-type="fig"}D), results that were confirmed by western blot for gRNA 2 (n = 1, antibiotic selection for dCas9^−VPR^) ([Figure S4](#mmc1){ref-type="supplementary-material"}A). *SNAP91* gRNA 2 also produced robust increases in *SNAP91* levels in NPCs (C1, 16.31-fold, p \< 0.0001; n = 9 each; antibiotic selection for dCas9^−VPR^) ([Figure 2](#fig2){ref-type="fig"}E). Of the three *CLCN3* gRNAs evaluated, only gRNA 3 increased expression in dCas9^−VPR^ NPCs (C2, 1.20-fold, p ≤ 0.05; C3, 1.27-fold, p ≤ 0.01; n = 3 each; no antibiotic selection for dCas9^−VPR^) ([Figure 2](#fig2){ref-type="fig"}F).

Altogether, these results demonstrate that designing three gRNAs is not necessarily sufficient to ensure successful manipulation of gene expression. Moreover, results are not always consistent across hiPSC-NPC lines derived from unique individuals. This variation could not be explained by differences in the levels of dCas9-effector protein ([Figure S2](#mmc1){ref-type="supplementary-material"}A) or transcript ([Figures S2](#mmc1){ref-type="supplementary-material"}B and S2C) between individuals. Therefore, we recommend validating gRNA efficacy across each individual hiPSC line to be evaluated.

Activating gRNAs Should Be Re-validated for dCas9^−KRAB^ Repression {#sec2.2}
-------------------------------------------------------------------

A key question is whether a gRNA position capable of activating transcript expression via dCas9^−VP64^ or dCas9^−VPR^ will also reliably repress transcription for the same gene via dCas9^−KRAB^. If true, this would reduce the necessary design, synthesis, cloning, and validation of different gRNAs for each experiment, facilitating more scalable experimental execution. We used the same gRNA positions examined in the activation setting ([Figure 2](#fig2){ref-type="fig"}), but in NPCs and neurons expressing dCas9^−KRAB^ fusion proteins ([Figure 3](#fig3){ref-type="fig"}). Again, both antibiotic-selected ([Figure S2](#mmc1){ref-type="supplementary-material"}) and non-selected lentiviral-transduced dCas9^−KRAB^ NPCs were evaluated. Overall, gRNA efficacies with dCas9^−KRAB^ ([Figure 3](#fig3){ref-type="fig"}) were only sometimes consistent with those achieved for dCas9^−VP64^ or dCas9^−VPR^ ([Figure 2](#fig2){ref-type="fig"}).Figure 3Repression of Neuropsychiatric Disorder Risk Genes in hiPSC-Derived NPCs and *NGN2* Neurons from Three Individuals(A--F) Normalized relative mRNA levels (compared with no gRNA control \[gray\]) following transduction of dCas9^KRAB^ NPCs (A, B, and E), 8-day-old (C and F), and 20-day-old (D) *NGN2* neurons with lentivirus-expressing gRNAs targeted to different locations (green, blue, and yellow) upstream of the TSS for *KCTD13* (A), *TAOK2* (B), *SNAP91* (C, D, and E), and *CLCN3* (F). C1--C3 indicates hiPSC lines from three independent male controls (see [Table S1](#mmc1){ref-type="supplementary-material"} for more information); each biological replicate is depicted by a circle.Data are presented as means ± SEM (bar graph) from at least three independent biological replicates. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001.

Whereas *KCTD13* gRNA 2 and 3 were efficacious in dCas9^−VP64^ NPC lines from two individuals ([Figure 2](#fig2){ref-type="fig"}A), no gRNAs produced significant effects in dCas9^−KRAB^ NPCs (using the stringent multiple comparison statistical analysis used throughout; antibiotic selection for dCas9^−KRAB^) ([Figure 3](#fig3){ref-type="fig"}A). Consistent with null effects observed in dCas9^−VP64^ NPCs ([Figure 2](#fig2){ref-type="fig"}B), none of the *TOAK2* gRNAs modulated transcription in dCas9^−KRAB^ NPCs (antibiotic selection for dCas9^−KRAB^) ([Figure 3](#fig3){ref-type="fig"}B).

gRNA positional efficacy for activation ([Figure 2](#fig2){ref-type="fig"}) and repression ([Figure 3](#fig3){ref-type="fig"}) was somewhat consistent with *SNAP91* (gRNA 2 \> gRNA 3/1) and *CLCN3* (gRNA 3 \> gRNA 1/2). Similar to results with dCas9^−VPR^, we found that *SNAP91* gRNA 2 had the most profound repressing effect in day 8 *NGN2* neuron populations (gRNA 2: C1, 0.43-fold, p \< 0.0001; C2, 0.31-fold, p \< 0.0001; C3, 0.24-fold, p \< 0.0001; n = 3 each; no antibiotic selection for dCas9^−KRAB^) ([Figure 3](#fig3){ref-type="fig"}C). *SNAP91* gRNA 2 also robustly decreased *SNAP91* levels in day 20 *NGN2* neurons (C1, 0.77-fold, p \< 0.001; n = 9 each; antibiotic selection for dCas9^−KRAB^) ([Figure 3](#fig3){ref-type="fig"}D). Surprisingly, when these same three gRNAs were tested in NPCs (rather than *NGN2* neurons) from these same three individuals, gRNA 3 rather than gRNA 2, showed greatest efficacy (C1, gRNA 2; 0.45-fold, p \< 0.0001/gRNA 3; 0.29-fold, p \< 0.0001; C2, gRNA 2; 0.46-fold, p \< 0.0001/gRNA 3; 0.28-fold, p \< 0.0001; C3, gRNA 2; 0.33-fold, p \< 0.0001/gRNA 3; 0.19-fold, p \< 0.0001; n = 3 each; antibiotic selection for dCas9^−KRAB^) ([Figure 3](#fig3){ref-type="fig"}E). Efficacy of gRNA 2 in decreasing SNAP91 protein levels was confirmed by western blot (n = 3; antibiotic selection for dCas9^−KRAB^) ([Figure S4](#mmc1){ref-type="supplementary-material"}B). Although gRNAs against *CLCN3* were generally less efficacious, gRNA 3 produced significant effects (gRNA 3: C1, 0.85-fold, p \< 0.01; C2, 0.74-fold, p \< 0.01; C3, 0.82-fold, p \< 0.01; n = 3 each; no antibiotic selection for dCas9^−KRAB^) in day 8 *NGN2* neuron populations from all three NPC lines tested ([Figure 3](#fig3){ref-type="fig"}F).

Overall, these results demonstrate that gRNAs designed upstream of the TSS and validated for dCas9^−VP64^ or dCas9^−VPR^ should not be assumed to be effective when combined with dCas9^−KRAB^. As observed with gene activation, dCas9^−KRAB^ results are not always consistent across unique individuals. Again, this variation could not be explained by differences in the levels of dCas9-effector protein ([Figure S2](#mmc1){ref-type="supplementary-material"}A) or transcript ([Figures S2](#mmc1){ref-type="supplementary-material"}B and S2C) between individuals. Surprisingly, in at least one case, gRNA efficacy in NPCs did not predict efficacy in neurons. We recommend validating gRNA efficacy across not just each individual hiPSC line to be evaluated, but also each dCas9 effector to be employed.

dCas9^−VP64^ Transcript Induction Efficacies Are Not Necessarily Consistent between NPCs, Neurons, Astrocytes, and HEK293T Cells {#sec2.3}
--------------------------------------------------------------------------------------------------------------------------------

Given that chromatin states, particularly nucleosome positioning, can differ between cell types ([@bib22]) and that nucleosomes can impede Cas9 access to DNA ([@bib19], [@bib20]), we next set out to determine whether gRNA activity in NPCs or neurons is predictive of efficacy in astrocytes. We differentiated astrocytes (NPC-astrocytes) ([@bib45], [@bib54]) ([Figure 4](#fig4){ref-type="fig"}A) from the antibiotic-selected dCas9^-VP64^ NPC lines. NPC-astrocytes are positive for the astrocyte markers S100β, GFAP, and EAAT1 ([Figures 4](#fig4){ref-type="fig"}A and 4B), and up to 90% of antibiotic-selected NPC-astrocytes were positive for dCas9 protein by fluorescence-activated cell sorting (FACS) ([Figure 4](#fig4){ref-type="fig"}C).Figure 4Activation of Neuropsychiatric Disorder Risk Genes in NPC-Derived Astrocytes from Three Individuals(A) Representative FACS validation of NPC-astrocytes, using antibodies for GFAP (left), S100β (middle), and EAAT1 (right).(B) Representative immunofluorescent image of NPC-astrocytes stained with vimentin (green) and DAPI (blue). Scale bar, 20 μm.(C) FACS validation of Cas9 protein levels in dCas9^-VP64^ NPC-astrocytes.(D and E) Normalized relative mRNA levels (compared with no gRNA control \[gray\]) following transduction of dCas9^VP64^ NPC-astrocytes with lentivirus-expressing gRNAs targeted to three different locations (green, blue, and yellow) upstream of the TSS for *KCTD13* (D) and *SNAP91* (E). C1--C3 indicates hiPSC lines from three independent male controls (see [Table S1](#mmc1){ref-type="supplementary-material"} for more information); each biological replicate is depicted by a circle.Data are presented as means ± SEM (bar graph) from at least three independent biological replicates. ^∗^p \< 0.05, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001.

Transcriptional activation in dCas9^−VP64^ NPC-astrocytes ([Figures 4](#fig4){ref-type="fig"}D and 4E) was inconsistent with results observed in dCas9^−VP64^ NPCs and neurons ([Figures 2](#fig2){ref-type="fig"}A, 2D, and 2E). For *KCTD13*, only gRNA 2, and only in one individual, increased expression (C2, 1.28-fold, p \< 0.05; n = 3; antibiotic selection for dCas9^−VP64^). Unexpectedly, NPC-astrocytes were surprisingly more amenable to transcriptional activation of *SNAP91* ([Figure 4](#fig4){ref-type="fig"}E) than NPCs or neurons ([Figures 2](#fig2){ref-type="fig"}D, 2E, and 2F). *SNAP91* gRNAs 2 and 3 produced dramatic increases in expression in NPC-astrocytes, two orders of magnitude larger than those observed in NPC or neurons (C1, gRNA 2; 458.5-fold, p \< 0.0001/gRNA 3; 405.5-fold, p \< 0.0001; C2, gRNA 2; 248.4-fold, p \< 0.0001/gRNA 3; 198.4-fold, p \< 0.0001; C3, gRNA 2; 564.7-fold, p \< 0.0001/gRNA 3; 467.7-fold, p \< 0.0001; n = 3 each; antibiotic selection for dCas9^−VP64^) ([Figure 4](#fig4){ref-type="fig"}E). Multiplexing of *SNAP91* gRNAs 1, 2, and 3 achieved greater efficacy than any single gRNA alone ([Figure 4](#fig4){ref-type="fig"}E).

There was surprisingly little correlation between gRNA efficacy in neural cells and HEK293T cells. While *KCTD13* gRNAs 2 and 3 proved efficacious in some (but not all) control dCas9^VP64^ NPCs, it was gRNAs 1 and 3 that increased expression in antibiotic-selected, but not unselected, dCas9^−VP64^ HEK293Ts ([Figure S5](#mmc1){ref-type="supplementary-material"}A). Although *TOAK2* gRNAs failed to increase expression in dCas9^VP64^ NPCs, gRNA 2 increased expression in antibiotic-selected, but not unselected, dCas9^−VP64^ HEK293Ts ([Figure S5](#mmc1){ref-type="supplementary-material"}B). Unexpectedly, *NRXN1* gRNAs 1--6 somewhat increased expression in antibiotic-selected dCas9^−VP64^ HEK293Ts, but not antibiotic-selected dCas9^−VPR^ HEK293Ts ([Figures S5](#mmc1){ref-type="supplementary-material"}C and S5D). Even more unexpectedly, while validated *CLCN3* gRNA 2 increased expression in dCas9^−VP64^ HEK293Ts ([Figure S5](#mmc1){ref-type="supplementary-material"}E), validated *SNAP91* gRNA 3 failed to increase expression in dCas9^−VP64^ HEK293Ts under any conditions ([Figure S5](#mmc1){ref-type="supplementary-material"}F).

We recommend validating gRNA efficacy across not just each individual hiPSC line to be evaluated and each dCas9 effector to be employed, but also each cell type to be characterized.

Non-integrative *In-Vitro-*Transcribed gRNAs Can Substitute for Lentiviral Delivery {#sec2.4}
-----------------------------------------------------------------------------------

Although gRNA-expressing lentiviral vectors efficiently modulate transcription, the cloning and the production of lentiviral particles will likely act as a technical bottleneck as this platform is expanded to higher-throughput applications. For one gene, using *SNAP91* gRNA 3, we tested the efficacy of a transiently expressed *in-vitro-*transcribed (IVT) gRNA to modulate transcription in antibiotic-selected dCas9^−VP64^ NPCs. Forty-eight hours after transfection, we observed robust upregulation of *SNAP91* in NPCs (C2, 6.13-fold, p \< 0.001; n = 3 each; antibiotic selection for dCas9^−VP64^) ([Figure 5](#fig5){ref-type="fig"}A). This magnitude of response was comparable with that achieved by stable lentiviral transduction ([Figure 2](#fig2){ref-type="fig"}), suggesting that transient IVT gRNAs might represent a more scalable strategy moving forward. Efficacy of IVT gRNA-mediated transcriptional activation was confirmed across two additional neural genes, *CEP162* (six pooled gRNAs) and *FUT9* (ten pooled gRNAs) ([Figure 5](#fig5){ref-type="fig"}A). Finally, we compared the efficacy of pools of ten, five (two independent pools), and one IVT gRNA(s) to modulate transcription in antibiotic-selected dCas9^−VP64^ NPCs. Forty-eight hours after transfection, we observed greatest upregulation of *FUT9* through multiplexing (C2, 10 gRNA pool, 3.3-fold, p \< 0.05; n = 3 each; antibiotic selection for dCas9^−VP64^) ([Figure 5](#fig5){ref-type="fig"}B).Figure 5Single and Multiplexed IVT gRNA-Mediated Transcriptional Modulation(A) Transient expression of IVT gRNAs for transcriptional modulation of *SNAP91* (1 gRNA), *CEP162* (six pooled gRNAs), and *FUT9* (ten pooled gRNAs). Normalized relative mRNA levels (compared with GFP \[*SNAP91*\] or ten gRNAs targeting a nearby non-promoter non-coding region \[*CEP162* and *FUT9*\]) following transfection of dCas9^VP64^ NPCs with IVT gRNAs targeted upstream of the TSS for *SNAP91*, *CEP162*, and *FUT9*.(B) Multiplexed pools of ten, five (two independent pools), and one IVT gRNA(s) for transcriptional modulation of *FUT9.*Data are presented as means ± SEM (bar graph) from at least three independent biological replicates. Each biological replicate is depicted by a circle. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001.

Discussion {#sec3}
==========

Dissecting the function of neuropsychiatric disorder-associated genes will greatly enhance our understanding of how specific variants contribute to disease risk. While dCas9 effectors are a novel platform for manipulating gene expression, we report a number of practical limitations that must be considered when designing hiPSC-based studies using this promising new tool. First, gRNA efficacies can vary between genes, individuals, neural cell types, and dCas9 effectors. Second, even the rational design of up to six different gRNAs does not guarantee that a functional gRNA will be validated. Moreover, gRNA efficacy seemed to be independent of dCas9 expression levels (data not shown) and/or antibiotic selection for dCas9 vectors ([Figures S2](#mmc1){ref-type="supplementary-material"} and [S4](#mmc1){ref-type="supplementary-material"}), suggesting there may not be a quick fix to facilitate transcriptional modulation of particularly intransient genes. Consequently, for hiPSC-based functional studies of neuropsychiatric disease risk genes, we advise that the extent of gRNA gene modulation be validated across each individual, cell type, and effector.

Given that such extensive validation would likely increase the time and cost involved in functional studies, and potentially preclude high-throughput analyses, a few alternative strategies might be employed. First, multiplexing many gRNAs in a single vector might increase the likelihood, not only that at least one gRNA is functional, but also that all gRNAs are expressed in each cell, thereby achieving more consistent effects than might be obtained using a pool of gRNA vectors. Second, because IVT gRNAs can substitute for lentiviral delivery, this would reduce the time and costs associated with vector design, construction, and viral packaging, while still being compatible with a multiplex strategy whereby many IVT gRNAs targeting the same gene could be transfected simultaneously. Our hope is that a threshold number of gRNAs will be empirically established, such that when they are combined in a multiplex strategy, there is a high degree of confidence that effective transcriptional modulation across all individuals and cell types of interest will be achieved.

Despite advances in gRNA design algorithms ([@bib5], [@bib11], [@bib12], [@bib53]), gRNA efficacy across individuals, cell types, and dCas9 effectors still must be empirically confirmed. We report clear cell line-dependent effects in gRNA efficacy and hypothesize that epigenetic differences drive this variability across our experiments. There is substantial evidence that the epigenetic landscape impacts gRNA efficacies, including chromatin structure ([@bib5], [@bib25], [@bib42], [@bib52]), nucleosome positioning ([@bib19]), and DNA methylation ([@bib52]). Histone modifications or competitive interactions with transcriptional machinery may also affect target site accessibility, although so far this has not been as well investigated. Overall, it seems that Cas9 activity is greatest at sites of open chromatin; because chromatin remodeling can restore Cas9 access ([@bib19]), it is possible that chromatin-modifying enzymes may improve efficacy, although the impact of such treatment on disease-modeling experiments is unknown. It is also possible that alternative and/or combinations of dCas9 effectors acting further from the promoter ([@bib16]) or that directly modify DNA ([@bib29]) or histone ([@bib24]) methylation may improve gRNA reliability across genes, individuals, and cell types. Finally, although not tested here, given the reported epigenetic differences between hiPSCs generated from the same individual ([@bib28], [@bib30], [@bib34], [@bib35], [@bib39]), it will be interesting to test to what extent gRNA efficacies can vary across isogenic NPCs, neurons, or astrocyte populations differentiated from independent hiPSCs from the same individual; of course, sequencing the promoter regions of each individual at each target gene would be necessary to rule out genetic effects.

Several groups have successfully applied the CRISPR-dCas9 system to modulate gene expression levels for large-scale genome-wide screens ([@bib4], [@bib15], [@bib18], [@bib26]). Our findings do not suggest that these dCas9 platforms are unsuitable for genome-wide approaches; rather, we only suggest that when focusing on a small number of candidate genes, it is prudent to always empirically establish the magnitude of gene expression modulation achieved. The successes of these CRISPR screens could reflect technical differences between our approaches (such as the levels of dCas9/gRNA expression, timing of dCas9 and/or gRNA selection, or the biology of specific cell lines used). We do not believe that the variability in gRNA efficacy reflects vector integration effects (such as differences in copy number or expression levels of dCas9 and/or gRNAs), as our FACS ([Figure S2](#mmc1){ref-type="supplementary-material"}A) and qPCR ([Figures S2](#mmc1){ref-type="supplementary-material"}B and S2C) data suggest that the difference in dCas9 expression across individuals is small, an observation that is consistent with findings that dCas9^−KRAB^ expression does not correlate to the level of changes gene expression achieved ([@bib10]). The generation of antibiotic selection of stable lines expressing dCas9^−VPR^, dCas9^−KRAB^, and dCas9-VP64 sometimes, but not always, improved gRNA efficacy in our hands. Owing to high transduction efficiencies observed with our (small) gRNA expression vectors, we did not test the impact of gRNA selection; nonetheless, it is possible that gRNA selection is a critical variable and/or that the timing of selection is important such that dCas9-effector and gRNA selection is more appropriately conducted concurrently instead of sequentially. More likely, the solution may simply entail multiplexing a variety of gRNAs simultaneously ([Figures 4](#fig4){ref-type="fig"}E and [5](#fig5){ref-type="fig"}B).

We were particularly interested in the synthetic activation of gene expression from the *NRNX1* locus, given the size and diverse alternative splice repertoire of its gene products; we were surprised at our inability to increase expression. We can only speculate that known ([@bib40]) or unknown epigenetic effects near the *NRXN1* promoter prevented us from increasing expression of this key neural gene in NPCs. Numerous factors have been hypothesized to affect gRNA efficacy for genome-editing purposes, including nucleosome positioning and 3D genome architecture of different cell types ([@bib43]), which can limit access of the gRNA to the target site. As our understanding of the epigenome grows, and with it our ability to better predict gRNA targets, we hope that dCas9-mediated transcriptional modulation will become a more robust and scalable technology.

Experimental Procedures {#sec4}
=======================

gRNA Design and Cloning {#sec4.1}
-----------------------

gRNAs were designed using either the optimized CRISPR (<http://crispr.mit.edu/>) or the CRISPR-ERA (<http://crispr-era.stanford.edu>) web tools. gRNAs were selected based on their specific locations at decreasing distances from the TSS as well as their lack of predicted off targets and E scores (<http://crispr-era.stanford.edu>). For lentiviral cloning: synthesized oligonucleotides (Thermo Fisher Scientific; [Table S2](#mmc1){ref-type="supplementary-material"}) were annealed (37°C for 30 min, 95°C for 5 min, ramp-down to 25°C at 5°C per min), diluted 1:100 and then ligated into BsmB1-digested lentiGuide-dTomato or lentiGuide-mTagBFP2-Puro (described below). For IVT production: PCR assembly of gRNA DNA template using synthetic forward and reverse oligonucleotides for SNAP91 ([Table S2](#mmc1){ref-type="supplementary-material"}) with the Tracr Fragment + T7 Primer Mix was performed as per GeneArt Precision gRNA Synthesis Kit (Thermo Fisher Scientific, A29377) instructions. The *SNAP91* gRNA was generated by *in vitro* transcription and purified as per the GeneArt Precision gRNA Synthesis Kit instructions.

Gibson Assembly of Vectors {#sec4.2}
--------------------------

Unless specified, all cloning reagents were from NEB and plasmid backbones were from Addgene (<https://www.addgene.org/>). Primers were synthesized by Thermo Fisher Scientific. All fragments were assembled using NEBuilder HiFi DNA Assembly Master Mix (NEB, no. E2621X). All assemblies were transformed into either DH5α Extreme Efficiency Competent Cells (Allele Biotechnology, no. ABP-CE-CC02050) or Stbl3 Chemically Competent *E. coli* (Thermo Fisher Scientific, no. C737303). Positive clones were confirmed by restriction digest and Sanger sequencing (GENEWIZ).

The following vectors have been deposited at Addgene: lenti-EF1a-dCas9^-VP64^-Puro, lenti-EF1a-dCas9^-VPR^-Puro, lenti-EF1a-dCas9^-KRAB^-Puro, lentiGuide-Hygro-mTagBFP2, lentiGuide-Hygro-eGFP, lentiGuide-Hygro-dTomato, lentiGuide-Hygro-iRFP670, and pLV-TetO-h*NGN2*-Neo.

### lentiGuide-dTomato and lentiGuide-mTagBFP2-Hygro {#sec4.2.1}

lentiGuide-Puro (Addgene, no. 52963) was digested with Mlu1 and BsiWI. dTomato was amplified from AAV-hSyn1-GCaMP6f-P2A-NLS-dTomato (Addgene, no.51085). HygroR sequence was amplified from lenti MS2-P65-HSF1_Hygro (Addgene, no. 61426). mTagBFP2 was amplified form pBAD-mTagBFP2 (Addgene, no. 3463). The P2A self-cleaving peptide sequence was amplified using a reverse primer of HygroR and forward primer of mTagBFP2. All gRNA sequences are provided in [Table S2](#mmc1){ref-type="supplementary-material"}.

### Lentiviral dCas9 Effectors {#sec4.2.2}

To engineer a lentiviral transfer vector that expresses dCas9:VP64-T2A-Puro (EF1a-NLS-dCas9(N863)-VP64-T2A-Puro-WPRE), dCas9:VP64-T2A-Blast (EF1a-NLS-dCas9(N863)-VP64-T2A-Blast-WPRE) (Addgene, no. 61,425) was digested with BsrGI and EcoRI. T2A-PuroR was amplified from pLV-TetO-hNGN2-P2A-eGFP-T2A-Puro (Addgene, no. 79823). Fragments were then assembled using NEBuilder HiFi DNA Assembly Master Mix (NEB, no. E2621). To engineer a lentiviral transfer vector that expresses dCas9:KRAB-Puro (EF1a-NLS-dCas9(N863)-KRAB-T2A-Puro-WPRE), dCas9:VP64-T2A-Blast (EF1a-NLS-dCas9(N863)-VP64-T2A-Blast-WPRE) (Addgene, no.61425) was first digested with BamHI and BsrGI. KRAB was then amplified from pHAGE-TRE-dCas9:KRAB (Addgene, no. 50917). Fragments were then assembled using NEBuilder HiFi DNA Assembly Master Mix. dCas9:KRAB-Blast was digested with BsrGI and EcoRI, and T2A-PuroR was amplified from pLV-TetO-hNGN2-P2A-eGFP-T2A-Puro (Addgene, no. 79823). Fragments were then assembled using NEBuilder HiFi DNA Assembly Master Mix. To engineer a lentiviral transfer vector that expresses dCas9:VPR-Puro (EF1a-NLS-dCas9(D10A, D839A, H840A, and N863A)-VPR-T2A-Puro-WPRE), dCas9:VPR was first amplified from SP-dCas9-VPR (Addgene, no. 63798), and T2A-PuroR was amplified from pLV-TetO-hNGN2-P2A-eGFP-T2A-Puro (Addgene, no. 79823). dCas9:KRAB-T2A-Puro was digested with BsiWI and EcoRI. Fragments were then assembled using NEBuilder HiFi DNA Assembly Master Mix.

Lentivirus Generation {#sec4.3}
---------------------

Lentiviruses were produced as described previously ([@bib1], [@bib17]). The lentiviral constructs expressing dCas9:VP64-T2A-Puro or dCas9:VPR-T2A-Puro or dCas9:KRAB-T2A-Puro (EF1α-dCas9:VP64-T2A-Puro or EF1α-dCas9:VPR-T2A-Puro or EF1α-dCas9:KRAB-T2A-Puro, respectively) are described above. Physical titration of lentivirus was performed by qPCR (qPCR Lentivirus Titration \[Titer\] Kit, ABMgood, no. LV900).

Generation of Antibiotic-Selected dCas9-VP64, dCas9-VPR, and dCas9-KRAB NPCs {#sec4.4}
----------------------------------------------------------------------------

NPCs per well (3.0 × 10^6^) were seeded onto growth factor-reduced Matrigel-coated six-well plates in NPC medium. The following day, lentiviruses generated as above using either the lentiviral vectors dCas9:VP64-T2A-Puro, dCas9:VPR-T2A-Puro, and dCas9:KRAB-T2A-Puro were added, and cultures were spinfected (1 hr, 1,000 × *g*, 25°C). Following spinfection, plates were transferred to a cell culture incubator for 3 hr. Medium was then removed and replaced with fresh NPC medium. Two days later, fresh NPC medium containing 1 μg/mL puromycin (Sigma, no. P7255) was added and cells were expanded in NPC medium containing 1 μg/mL puromycin followed by banking in liquid nitrogen. Once thawed, NPCs were grown in NPC medium containing 1 μg/mL puromycin for the remainder of the experiment. Antibiotic-selected NPC lines were validated via FACS using an antibody for Cas9. Vendors, catalog numbers, and dilutions of all antibodies used are listed in [Table S4](#mmc1){ref-type="supplementary-material"}.

Transduction of dCas9-Effector NPCs with gRNA Lentivirus {#sec4.5}
--------------------------------------------------------

dCas9-effector NPCs per well (3.5 × 10^5^) were seeded onto growth factor-reduced Matrigel-coated 24-well plates in NPC medium containing 1 μg/mL puromycin. The next day, lentiviruses generated as above were added and cultures were spinfected (1 hr, 1,000 × *g*, 25°C). Following spinfection, plates were transferred to a cell culture incubator for 3 hr. The medium was then removed and replaced with fresh NPC medium containing 1 μg/mL puromycin. Cells were harvested 48 hr later.

Transduction of Antibiotic-Selected dCas9-VP64 NPC-Astrocytes with gRNA Lentivirus {#sec4.6}
----------------------------------------------------------------------------------

Antibiotic-selected dCas9-VP64 NPC-astrocytes per well (1 × 10^5^) were seeded onto growth factor-reduced Matrigel-coated 24-well plates in Astrocyte medium containing 1 μg/mL puromycin. The next day, lentiviruses generated as above were added and cultures were spinfected (1 hr, 1,000 × *g*, 25°C). Following spinfection, plates were transferred to a cell culture incubator for 3 hr. Medium was then removed and replaced with fresh Astrocyte medium containing 1 μg/mL puromycin. Cells were harvested 48 hr later.

Transfection of Antibiotic-Selected dCas9-Effector NPCs with IVT gRNA {#sec4.7}
---------------------------------------------------------------------

Antibiotic-selected dCas9-effector NPCs per well (4.0 × 10^5^) were added to growth factor-reduced Matrigel-coated 24-well plates in NPC medium containing 1 μg/mL puromycin. *SNAP91* gRNA\#2 IVT product (600 ng) and 2 μL of EditPro Stem Transfection Reagent (MTI-GlobalStem, no. GST-2174), diluted in 50 μL of Opti-MEM (Thermo Fisher Scientific, no. 31985062) was added drop wise directly after. Cells were harvested 48 hr later.

Real-Time qPCR {#sec4.8}
--------------

Total RNA was extracted using TRIzol following the manufactures instructions. Transcript analysis was carried out using a QuantStudio 7 Flex Real-Time PCR System using the Power SYBR Green RNA-to-Ct Real-Time qPCR Kit for primers (all Thermo Fisher Scientific). RNA template (50 ng) was added to the PCR mix, containing primers detailed in [Table S3](#mmc1){ref-type="supplementary-material"} (Thermo Fisher Scientific). qPCR conditions were as follows, 48°C for 15 min, 95°C for 10 min followed by 40 cycles (95°C for 15 s, 60°C for 60 s).

Live-Cell Fluorescent Protein Detection {#sec4.9}
---------------------------------------

Cells were dissociated using Accutase, washed with DMEM, and resuspended in FACS buffer (1× PBS \[without Mg^2+^/Ca^2^\] containing 1%, v/v, BSA and TO-PRO3 \[1 μM, Thermo Fisher Scientific\] and filtered using a 40-μm filter \[BD Biosciences\]). Cytometry was performed using an LSR II or FACS Canto (BD Biosciences) and analysis was performed using FlowJo (v.8.7.3, Tree Star).

Data Analysis {#sec4.10}
-------------

All qPCR data represent at least three independent biological experiments. Data were analyzed using GraphPad Prism 6 software. Values are expressed as means ± SEM. Statistical significance was tested using one-way ANOVA with Tukey\'s *post hoc* test for comparison of all sample means. ^∗^p \< 0.05, ^∗∗^p \< 0.01, ^∗∗∗^p \< 0.001, ^∗∗∗∗^p \< 0.0001.

Human subjects work on these de-identified control hiPSCs was approved by the Institutional Review Board at Icahn School of Medicine.
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